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Hotspots in Neuro-Oncology
Michael Weller
From the Department of Neurology, University Hospital Zurich, Switzerland
  Rituximab Is Associated with Improved 
Survival for Aggressive B cell CNS Lym-
phoma
Gregory G, et al. Neuro-Oncology 2013; 15: 1068–73.
Despite the absence of evidence for its activity, the CD20 an-
tibody rituximab has been broadly introduced into the prima-
ry treatment of primary central nervous system lymphoma 
(PCNSL). In the August issue, Gregory et al from Austral-
ia sought to validate this approach by a retrospective study of 
128 patients with PCNSL treated with or without rituximab. 
On univariate analysis, younger age, ECOG performance sta-
tus 0 or 1, normal lactate dehydrogenase, diagnosis after 2004, 
and treatment with cytarabine and rituximab were predictive 
of favourable overall survival. On multivariate analysis, only 
age was an independent predictor of survival. The interpreta-
tion of these results is difficult. Given that treatment outcome 
is likely to improve due to many reasons over time and that 
multivariate analysis failed to show a role either for rituximab 
or for treatment after 2004, I doubt that this data can be used 
to justify the routine introduction of rituximab into standards 
of care for PCNSL. Prospective randomised trials are the only 
way to move this complex field forward.
  Subsequent Brain Tumors in Patients 
with Autoimmune Disease
Hemminki K, et al. Neuro-Oncology 2013; 15: 1142–50.
Interrelations between various autoimmune diseases and the 
incidence and cause of various brain tumours have remained 
a controversial topic in the epidemiology of brain tumours. 
No firm conclusions have been derived from previous stud-
ies. For the present study, data were derived from Sweden. 
Data on 402,462 patients hospitalised for autoimmune diseas-
es were studied, brain tumour risks and survival were analyzed 
and compared with that of the general population. Among 33 
auto immune diseases, none had an impact on the incidence of 
brain tumours; however, there was a negative impact on sur-
vival both in gliomas and in meningiomas. The reasons for this 
remain unclear but may include enhanced physical disability 
or under-treatment because of limitations of cancer treatment 
by the pre-existing autoimmune disorder. Thus, while there 
have been claims that gliomas may even be underrepresented 
in patients with allergies because of enhanced immune reac-
tivity, no link between the evolution of brain tumours and au-
toimmune dysfunction was disclosed here.
  Memantine for the Prevention of Cogni-
tive Dysfunction in Patients Receiving 
Whole-Brain Radiotherapy:  
A Randomized, Double-Blind, Placebo-
Controlled Trial
Brown PD, et al. Neuro-Oncology 2013; 15: 1429–37.
Whole-brain radiotherapy has been increasingly challenged 
in the treatment of various neuro-oncological conditions be-
cause of insufficient efficacy and its unfavourable, notably 
long-term safety profile. Efforts at improving or maintain-
ing cognitive function in irradiated patients have so far not 
been successful. In the October issue, Brown et al, for the Ra-
diation Therapy Oncology Group (RTOG), presented results 
of a randomised controlled trial which assessed the possible 
benefit of the candidate neuroprotective agent, memantine, in 
brain metastasis patients treated with whole-brain radiothera-
py. Although the mode of action of memantine in other neu-
rological conditions has not been fully clarified, antagonism 
at the  N-methyl-D-aspartate type of the glutamate receptor is 
currently thought to mediate these effects. Although the trial 
failed to meet the primary endpoint, in part as a result of insuf-
ficient power, secondary endpoints and subgroup analysis in-
dicated that memantine-treated patients had superior cognitive 
function over time. These interesting results provide support 
for further exploration of similar pharmacological approaches 
in patients with brain metastases for whom whole-brain radio-
therapy seems to be indicated and indispensable. Various can-
didate drugs are in principle available and similar trials are ea-
gerly awaited.
  The Immune Cell Infiltrate Populating 
Meningiomas is Composed of Mature, 
Antigen-Experienced T and B Cells
Fang L, et al. Neuro-Oncology 2013; 15: 1479–90.
Meningioma is not commonly a tumour considered to trig-
ger a significant immune response. Moreover, it has not been 
a target disease for the increasing number of immunothera-
py approaches currently applied to other brain tumours, no-
tably glioblastoma. In the November issue, Fang et al assess 
the immune cell infiltrate of a serious of 28 meningiomas and 
observed significant numbers of B and T cells, in particular 
around vessels. In most tumours, flow cytometry of ex vivo 
harvested tumour tissue was used to further characterise T cell 
phenotypes. The tumours commonly contained antigen-ex-
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perienced CD4+ and CD8+ memory/effector T cells, regula-
tory T cells, and T cells expressing PD-1 und Tim-3. These 
T cell populations were enriched compared with peripheral 
blood. These studies highlight that there are specific interac-
tions even between meningiomas and the immune system and 
illustrate the possibility for future immunological approaches 
particularly in tumours where surgical and radio-oncological 
treatment strategies have failed.
  Seizure Control Following Radiotherapy 
in Patients with Diffuse Gliomas: A Ret-
rospective Study
Rudà R, et al. Neuro-Oncology 2013; 15: 1739–49.
Symptomatic epilepsy is a common presenting sign and as-
sociated with significant impairment of quality of life in pa-
tients with low-grade gliomas. Since imaging endpoints have 
remained controversial in these patients, measures of clinical 
benefit would be helpful in defining a role for any treatment in 
patients with low-grade gliomas. In the December issue, Rudà 
et al reported on the effect on seizure control of radiotherapy 
in patients with diffuse gliomas. In a retrospective study of 43 
patients with low-grade gliomas, there was a significant re-
duction of seizure frequency in 31 of 43 patients (73 %) at 3 
months after radiotherapy. Seizure freedom was achieved in 
32 % of all patients at 12 months. Effects on seizures were not 
necessarily reflected by effects visible on MR imaging. These 
interesting study results suggest that the impact of therapeutic 
measures for low-grade gliomas on seizure frequency should 
be incorporated as an endpoint in future clinical trials.
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On multivariate analysis only age was an independent predictor of survival. The 
interpretation of these results is difficult. Given that treatment outcome is likely to 
improve due to many reasons over time and that the multivariate analysis failed to 
show a role either for rituximab or for treatment after 2004, I doubt that this data can 
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unfavorable, notably long term safety profile. Efforts at improving or maintaining 
cognitive function in irradiated patients have so far not been successful. In the 
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Symptomatic epilepsy is a common presenting sign and associated with significant 
impairment of quality of life in patients with low-grade gliomas. Since imaging 
endpoints have remained controversial in these patients, measures of clinical benefit 
would be helpful in defining a role for any treatment in patients with low grade 
gliomas. In the December issue, Rudà and colleagues reported on the effect on 
seizure control of radiotherapy in patients with diffuse gliomas. In a retrospective 
study of 43 patients with low-grade gliomas, there was a significant reduction of 
seizure frequency in 31 of 43 patients (73%) at 3 months after radiotherapy. Seizure 
freedom was achieved in 32% of all patients at 12 months. Effects on seizures were 
not necessarily reflected by effects visible on MR imaging. These interesting study 
results suggest that the impact of therapeutic measures for low-grade gliomas on 
seizure frequency should be incorporated as an endpoint in the future in clinical trials. 
 
 
